37Z Stock Overview
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Allakos Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.99 |
52 Week High | US$4.97 |
52 Week Low | US$0.93 |
Beta | 0.81 |
1 Month Change | -15.57% |
3 Month Change | -9.27% |
1 Year Change | -75.93% |
3 Year Change | -98.88% |
5 Year Change | -97.30% |
Change since IPO | -96.81% |
Recent News & Updates
Recent updates
Shareholder Returns
37Z | DE Biotechs | DE Market | |
---|---|---|---|
7D | -3.7% | -5.1% | -2.0% |
1Y | -75.9% | -21.1% | -0.3% |
Return vs Industry: 37Z underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 37Z underperformed the German Market which returned -0.3% over the past year.
Price Volatility
37Z volatility | |
---|---|
37Z Average Weekly Movement | 10.8% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 37Z's share price has been volatile over the past 3 months.
Volatility Over Time: 37Z's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 131 | Robert Alexander | www.allakos.com |
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Allakos Inc. Fundamentals Summary
37Z fundamental statistics | |
---|---|
Market cap | €88.27m |
Earnings (TTM) | -€174.34m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 37Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
37Z income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$185.70m |
Earnings | -US$185.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.11 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 37Z perform over the long term?
See historical performance and comparison